ネクセラファーマの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2021/02/03 | 2,004 | 2,050 | 1,995 | 2,025 | +31 | +1.6% | 667,300 |
| 2021/02/02 | 2,048 | 2,059 | 1,993 | 1,994 | -47 | -2.3% | 696,400 |
| 2021/02/01 | 1,961 | 2,048 | 1,960 | 2,041 | +71 | +3.6% | 679,300 |
| 2021/01/29 | 1,970 | 2,048 | 1,958 | 1,970 | -21 | -1.1% | 931,800 |
| 2021/01/28 | 1,970 | 2,004 | 1,966 | 1,991 | -29 | -1.4% | 779,900 |
| 2021/01/27 | 2,000 | 2,047 | 1,974 | 2,020 | +20 | +1% | 631,000 |
| 2021/01/26 | 2,075 | 2,078 | 1,991 | 2,000 | -77 | -3.7% | 1,036,100 |
| 2021/01/25 | 2,089 | 2,098 | 2,033 | 2,077 | +9 | +0.4% | 514,400 |
| 2021/01/22 | 2,047 | 2,104 | 2,045 | 2,068 | -1 | ±0% | 982,100 |
| 2021/01/21 | 1,982 | 2,086 | 1,981 | 2,069 | +88 | +4.4% | 1,392,800 |
| 2021/01/20 | 1,960 | 1,999 | 1,946 | 1,981 | +50 | +2.6% | 814,200 |
| 2021/01/19 | 1,979 | 1,987 | 1,927 | 1,931 | -40 | -2% | 647,200 |
| 2021/01/18 | 1,930 | 2,022 | 1,929 | 1,971 | +23 | +1.2% | 1,193,900 |
| 2021/01/15 | 1,948 | 1,976 | 1,931 | 1,948 | +3 | +0.2% | 816,300 |
| 2021/01/14 | 1,929 | 1,978 | 1,920 | 1,945 | ±0 | ±0% | 769,900 |
| 2021/01/13 | 1,998 | 2,040 | 1,936 | 1,945 | -54 | -2.7% | 1,338,000 |
| 2021/01/12 | 1,936 | 2,059 | 1,921 | 1,999 | +39 | +2% | 2,130,700 |
| 2021/01/08 | 1,897 | 1,986 | 1,885 | 1,960 | +91 | +4.9% | 2,239,600 |
| 2021/01/07 | 1,830 | 1,910 | 1,828 | 1,869 | +105 | +6% | 2,103,800 |
| 2021/01/06 | 1,688 | 1,777 | 1,655 | 1,764 | +53 | +3.1% | 1,754,900 |
| 2021/01/05 | 1,768 | 1,768 | 1,697 | 1,711 | -59 | -3.3% | 955,600 |
| 2021/01/04 | 1,808 | 1,821 | 1,757 | 1,770 | -30 | -1.7% | 733,500 |
| 2020/12/30 | 1,807 | 1,831 | 1,791 | 1,800 | -20 | -1.1% | 540,300 |
| 2020/12/29 | 1,822 | 1,852 | 1,816 | 1,820 | +19 | +1.1% | 662,400 |
| 2020/12/28 | 1,809 | 1,840 | 1,754 | 1,801 | -48 | -2.6% | 1,391,600 |
| 2020/12/25 | 1,830 | 1,900 | 1,830 | 1,849 | -1 | -0.1% | 1,646,600 |
| 2020/12/24 | 1,765 | 1,863 | 1,764 | 1,850 | +125 | +7.2% | 2,447,500 |
| 2020/12/23 | 1,736 | 1,793 | 1,700 | 1,725 | -20 | -1.1% | 2,222,600 |
| 2020/12/22 | 1,645 | 1,765 | 1,644 | 1,745 | +100 | +6.1% | 2,954,700 |
| 2020/12/21 | 1,699 | 1,699 | 1,612 | 1,645 | +97 | +6.3% | 1,502,200 |
| 2020/12/18 | 1,538 | 1,558 | 1,528 | 1,548 | +4 | +0.3% | 371,500 |
| 2020/12/17 | 1,552 | 1,566 | 1,540 | 1,544 | -8 | -0.5% | 359,900 |
| 2020/12/16 | 1,589 | 1,603 | 1,544 | 1,552 | -41 | -2.6% | 620,300 |
| 2020/12/15 | 1,610 | 1,617 | 1,546 | 1,593 | -27 | -1.7% | 1,074,700 |
| 2020/12/14 | 1,617 | 1,640 | 1,609 | 1,620 | -10 | -0.6% | 304,400 |
| 2020/12/11 | 1,656 | 1,656 | 1,616 | 1,630 | +9 | +0.6% | 497,100 |
| 2020/12/10 | 1,671 | 1,674 | 1,613 | 1,621 | -59 | -3.5% | 658,000 |
| 2020/12/09 | 1,641 | 1,690 | 1,616 | 1,680 | +45 | +2.8% | 785,500 |
| 2020/12/08 | 1,615 | 1,654 | 1,610 | 1,635 | +10 | +0.6% | 565,300 |
| 2020/12/07 | 1,680 | 1,680 | 1,598 | 1,625 | -47 | -2.8% | 892,300 |
| 2020/12/04 | 1,669 | 1,675 | 1,636 | 1,672 | -5 | -0.3% | 754,700 |
| 2020/12/03 | 1,704 | 1,710 | 1,670 | 1,677 | -23 | -1.4% | 755,300 |
| 2020/12/02 | 1,712 | 1,782 | 1,670 | 1,700 | +55 | +3.3% | 3,189,700 |
| 2020/12/01 | 1,592 | 1,656 | 1,592 | 1,645 | +63 | +4% | 1,081,700 |
| 2020/11/30 | 1,589 | 1,602 | 1,544 | 1,582 | +15 | +1% | 803,000 |
| 2020/11/27 | 1,556 | 1,595 | 1,555 | 1,567 | -8 | -0.5% | 694,000 |
| 2020/11/26 | 1,519 | 1,585 | 1,506 | 1,575 | +52 | +3.4% | 1,211,900 |
| 2020/11/25 | 1,482 | 1,527 | 1,460 | 1,523 | +47 | +3.2% | 919,700 |
| 2020/11/24 | 1,525 | 1,534 | 1,446 | 1,476 | -37 | -2.4% | 3,451,500 |
| 2020/11/20 | 1,382 | 1,636 | 1,382 | 1,513 | +119 | +8.5% | 9,775,700 |
901～
950
件表示中 / 4944件
類似銘柄と比較する
現在ご覧いただいている「ネクセラファーマ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| ネクセラファーマ | 125,100円 | +197.7% | - | 0.00% | 51.12倍 | 1.63倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ゼリア新薬 | 233,800円 | +9.6% | +17.5% | 1.97% | 13.21倍 | 1.29倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| 鳥居薬 | 393,500円 | +11.1% | +20.6% | 3.05% | 23.05倍 | 0.92倍 |
|
ＪＴ傘下。柱の抗ＨＩＶ薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
| 杏林製薬 | 153,100円 | +3.2% | +4.5% | 3.40% | 17.59倍 | 0.67倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| 栄研化 | 246,000円 | +7.6% | +57.5% | 2.15% | 19.02倍 | 1.87倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
